COMP <GO>
NUS vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Nu Skin Enterprises Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NUS 3
— JNJ 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $4.69 (-1.47%) • MKT CAP: $228.3M
roic
6.70%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.40% | 67.90% | +1.50 | NUS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 6.70% | 25.50% | -18.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 20.15% | 2.97% | +17.18 | NUS | /fcf-yield <GO> |
| Operating Margin | 4.40% | 34.70% | -30.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 28.50% | -17.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -14.30% | 6.00% | -20.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.18% | 0.00% | +5.18 | NUS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.59 | -2.05 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 62.1 | -16.90 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $228.3M | $662.49B | -$662.26B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUS REV | JNJ REV | NUS GROSS % | JNJ GROSS % | NUS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.49B | $94.19B | 69.4% | 67.9% | $46.0M | $19.70B |
| FY 2024 | $1.73B | $88.82B | 68.2% | 69.1% | $70.2M | $19.84B |
| FY 2023 | $1.97B | $85.16B | — | — | $118.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUS // BETA —
JNJ // BETA 1.08